148 related articles for article (PubMed ID: 10753831)
21. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
[TBL] [Abstract][Full Text] [Related]
22. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.
Yonemura Y; Miyake H; Asou N; Mitsuya H
Int J Hematol; 2005 Nov; 82(4):307-9. PubMed ID: 16298819
[TBL] [Abstract][Full Text] [Related]
24. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
Basser RL
Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
[TBL] [Abstract][Full Text] [Related]
25. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
[TBL] [Abstract][Full Text] [Related]
26. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
[TBL] [Abstract][Full Text] [Related]
27. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
[TBL] [Abstract][Full Text] [Related]
28. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia.
Adams JA; Liu Yin JA; Brereton ML; Briggs M; Burgess R; Hyde K
Br J Haematol; 1997 Oct; 99(1):139-46. PubMed ID: 9359514
[TBL] [Abstract][Full Text] [Related]
29. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
Ide Y; Harada K; Imai A; Yanagida M
Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans.
De Boer RH; Roskos LK; Cheung E; Fox S; Basser RL; Marty J; Begley CG; Cebon J
Growth Factors; 2000; 18(3):215-26. PubMed ID: 11334057
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia.
Geissler K; Kabrna E; Stengg S; Schwarzinger I; Knöbl P; Valent P; Eichinger S; Barge A; Lechner K
Br J Haematol; 1998 Jul; 102(2):535-43. PubMed ID: 9695971
[TBL] [Abstract][Full Text] [Related]
32. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
Sheridan W; Menchaca D
Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
[TBL] [Abstract][Full Text] [Related]
33. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
[TBL] [Abstract][Full Text] [Related]
34. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
Moore JO; Dodge RK; Amrein PC; Kolitz J; Lee EJ; Powell B; Godfrey S; Robert F; Schiffer CA
Blood; 1997 Feb; 89(3):780-8. PubMed ID: 9028308
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
Farese AM; MacVittie TJ; Roskos L; Stead RB
Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
[TBL] [Abstract][Full Text] [Related]
37. What is the potential for thrombopoietic agents in acute leukemia?
Kuter DJ
Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
[TBL] [Abstract][Full Text] [Related]
38. Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model.
Nishiyama U; Kuwaki T; Akahori H; Kato T; Ikeda Y; Miyazaki H
J Thromb Haemost; 2005 Feb; 3(2):355-60. PubMed ID: 15670044
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
40. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]